MWMatti Waterman

Matti Waterman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Matti Waterman has a total of 81 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience

    by Lev Lichtenstein, Benjamin Koslowsky, Ami Ben Ya’acov, Irit Avni-Biron, Baruch Ovadia, Ofer Ben-Bassat, Timna Naftali, Uri Kopylov, Yael Haberman, Hagar Banai Eran, et al.

    Background: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated inflammatory bowel diseases (IBD) affecting millions of people worldwide. IBD therapies, designed for continuous immune suppression, often render patients more susceptible to infections. The effect of the immune suppression on the risk of coronavirus disease-19 (COVID-19) is not fully determined yet. Objective: To describe COVID-19 characteristics and outcomes and to evaluate the association between IBD phenotypes, infection outcomes and immunomodulatory therapies. Methods: In this multi-center study, we prospectively followed IBD patients with proven COVID-19. De-identified data from medical charts were collected including age, gender, IBD type, IBD clinical activity, IBD treatments, comorbidities, symptoms and outcomes of COVID-19. A multivariable regression model was used to examine the effect of immunosuppressant drugs on the risk of infection by COVID-19 and the outcomes. Results: Of 144 IBD patients, 104 (72%) were CD and 40 (28%) were UC. Mean age was 32.2 ± 12.6 years. No mortalities were reported. In total, 94 patients (65.3%) received biologic therapy. Of them, 51 (54%) at escalated doses, 10 (11%) in combination with immunomodulators and 9 (10%) with concomitant corticosteroids. Disease location, behavior and activity did not correlate with the severity of COVID-19. Biologics as monotherapy or with immunomodulators or corticosteroids were not associated with more severe infection. On the contrary, patients receiving biologics had significantly milder infection course (p = 0.001) and were less likely to be hospitalized (p = 0.001). Treatment was postponed in 34.7% of patients until recovery from COVID-19, without consequent exacerbation. Conclusion: We did not witness aggravated COVID-19 outcomes in patients with IBD. Patients treated with biologics had a favorable outcome.


  • Open Access

    P570 Prediction of achieving remission in Crohn’s disease patients by abdominal Imaging

    by H Meringer, R Tzadok, D Mercer, M Handler, S Barnes, M Waterman, S Abadi, R Margalit Yehuda, U Kopylov, M M Amitai, et al.

    Vedolizumab (VDZ) is an effective therapy in patients with Crohn’s disease (CD). Early prediction of response remains an unmet need. We aimed to evaluate whether abdominal imaging can predict response to VDZ. Abdominal imaging [Computed tomography enterography (CTE) or magnetic resonance enterography (MRE)] of CD patients initiating therapy with VDZ was evaluated, up to 4 months before VDZ initiation. Response to VDZ was determined at week 26 using the Harvey–Bradshaw index (HBI) or the Crohn’s Disease Activity Index (CDAI), in cases no objective score was available it was defined based on the physician assessment. Thirty-three CD patients were included. At week 26, clinical response and remission were achieved in 20(60.6%) and 14(42.4%) patients, respectively. CRP and Calprotectin levels were available for 22/33 and 7/33 patients at week 26. As expected, levels trended lower in remission versus no remission- median CRP 2.41mg/L [IQR 1.3–4.5] vs 10.2[1.6–44.6], p=0.11 and 23.5 µg/g [5–42] vs 2002.8[191–2003], p=0.095, though this did not reach statistical significance. Clinical remission versus no remission was significantly associated with being biologic naïve, 8/14 vs 2/19 (p=0.01) and no prior CD surgeries, 10/14 vs 6/19 (p=0.04). Characteristics of local inflammation as mural edema, fibrofatty proliferation or lymphadenopathy were higher in patients achieving remission versus non-remission. The presence of either mural edema or fibro-fatty proliferation was significantly associated with remission (12/14 vs 9/19, p=0.03). The presence of stenosis in imaging was nominally higher in patients failing to achieve remission (14/19 vs 6/14, p=0.15). Number of diseased segments, length of inflammation or the maximal bowel thickness were similar in remission and no-remission. Baseline imaging may help to predict remission based on the presence of either mural edema or fibrofatty proliferation and the absence of stenosis

  • 739 - A Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Mild to Moderate Ulcerative Colitis: Results of a Phase 2A Clinical Trial Showing Promising Results

    by Einat Almon, Eran Goldin, Wisam Sbeit, Eran Israeli, Doron Schwartz, Ofer Ben-Bassat, Matti Waterman, Nikola Milinic, Boris Vladimirov, Mali Szlaifer, et al.


    • 1 December 2009
      • Vol. 11  (12) , 730-4

    Aspirin promotes low density lipoprotein susceptibility to oxidative modification in healthy volunteers.

    by Matti Waterman, Bianca Fuhrman, Shlomo Keidar, Tony Hayek

    Low density lipoprotein oxidation is a major pathogenic pathway in atherosclerosis. Previous studies suggested that aspirin, a commonly prescribed drug in patients with atherosclerosis, when given in a dose of 300 mg/day may decrease LDL susceptibility to oxidative modification. However, the effect of the more common lower dose aspirin on LDL oxidation is not known. To examine the effect of aspirin administration (low dosage) on the susceptibility of LDL to oxidative modification in healthy volunteers. Aspirin 75 mg was administered daily for 2 weeks to 10 healthy volunteers selected from the medical staff and students at the faculty of medicine. The main outcome measure was ex vivo oxidation of LDL by ultraviolet C irradiation or by peroxyl free radicals generated by AAPH (2,2'-azobis 2-amidinopropane hydrochloride). The extent of LDL oxidation was determined by measuring the formed amounts of thiobarbituric acid-reactive substances, lipid peroxides and conjugated dienes. Following exposure to UVc irradiation there was a significant (P 0.01) increase (10.8%) in TBARS concentrations and a significant (P < 0.05) increase (5.4%) in PD concentrations in LDL withdrawn after aspirin treatment as compared to LDL withdrawn before aspirin treatment. Following incubation with AAPH there was a significant (P < 0.05) increase (15%) in PD concentrations and a significant (P < 0.05) reduction (10%) of the LDL oxidation lag time in LDL withdrawn after aspirin intake as compared to LDL withdrawn before aspirin treatment. Aspirin treatment given to healthy volunteers at a dose of 75 mg/day increased the susceptibility of their plasma LDL to oxidative modification ex vivo. Our study provides, for the first time, in vivo evidence of pro-oxidative properties of aspirin already suggested by previous in vitro trials.


  • W1981 Lysyl Oxidase Like Protein 2 (Loxl2) and Loxl3 Expression Is Up-Regulated in Colorectal Carcinoma

    by Matti Waterman, Shelly Zafriar, Rami Eliakim, Ofer Ben-Izhak, Gera Neufeld

    • 1 November 2006
      • Vol. 145  (11) , 789-92, 864

    [The significance of IL-13 gene +2044G/A mutation in patients with inflammatory bowel disease].

    by Matti Waterman, Amir Karban, Shula Nesher, Batia Weiss, Raanan Shamir, Rami Eliakim

    Inflammatory bowel disease (IBD) is caused by a combination of genetic, immunological and environmental factors. Despite recent advances in the study of IBD pathogenesis, including the discovery of the NOD2/CARD15 mutation in 40% of Crohn's Disease (CD) patients, in most IBD patients no known mutations have yet been discovered. The interleukin (IL)-13 gene is located near the IBD5 locus on chromosome 5q31, known to be in linkage disequilibrium with CD. IL-13 has a role in the pathogenesis of several chronic inflammatory diseases including IBD. The +2044G/A mutation, which encodes an IL-13 protein with glutamine instead of arginine, has been associated with various inflammatory conditions. However, its role in IBD has not been defined. This is a study of the role of the IL-13 gene +2044G/A mutation in the susceptibility to and phenotype of IBD. Two hundred and eighty-five patients with CD and 111 cases of ulcerative colitis (UC) were enrolled in the study. Mutation frequency was determined using restriction fragment length polymorphism study in IBD patients and 178 healthy ethnically matched controls. The mutated allele frequency was determined in various clinical sub-groups of IBD patients. Statistical significance of the differences in allele frequency in CD and UC patients and healthy controls was determined. The +2044G/A allele frequency was similar in CD, UC and healthy controls (23.3%, 19.4%, 19.6%, respectively, p = 0.294). There was no significant association of +2044G/A mutation carriage with specific phenotypes of CD and UC. The IL-13 gene +2044G/A mutation has no significant role in susceptibility to and phenotype of IBD.